A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.

Mansoor Raza Mirza,Christiane Ehlers Mortensen,René dePont Christensen,Louise Christoffersen,Mia Westergaard,Louisa Boufercha,Michael J. Birrer,Elisabeth Åvall-Lundqvist,Line Bjørge,Johanna Mäenpää,Nsgo

A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.

2016

Mansoor Raza Mirza
Christiane Ehlers Mortensen
René dePont Christensen
Louise Christoffersen
Mia Westergaard
Louisa Boufercha
Michael J. Birrer
Elisabeth Åvall-Lundqvist
Line Bjørge
Johanna Mäenpää
Nsgo

5555Background: PARP-inhibitors and anti-angiogenic agents are active substances against ovarian cancer (OC). We investigated the safety, tolerability and Recommended Phase 2 Dose (RP2D) of the com...

Keywords:

Ovarian cancer
Bevacizumab
Pathology
Cancer research
Platinum
Medicine
Tolerability
in patient
Oncology
Internal medicine
platinum sensitive
phase i study
epithelial ovarian cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations